Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.53 |
| ▸ | DRD2 | P14416 | 11/20 | 0.53 |
| ▸ | MC4R | P32245 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20651289 | 0.76 | CACNA2D1 (0.41) | MC4RMEN1KMT2A | |
| SCHEMBL7664498 | 0.73 | DRD4 (0.53) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL10502128 | 0.72 | POLB (0.70) | DRD4POLBFAAHKMT2ALMNA | |
| SCHEMBL13149275 | 0.72 | ALDH1A1 (0.77) | POLBFAAHMEN1KMT2ALMNA | |
| SCHEMBL7369921 | 0.71 | ALDH1A1 (0.73) | DRD4POLBFAAHKMT2ALMNA | |
| SCHEMBL18707926 | 0.71 | GAA (0.51) | MC4R | |
| Hydrochloric Acid SCHEMBL10502730 | 0.70 | POLB (0.67) | DRD4POLBFAAHKMT2ALMNA | |
| SCHEMBL5152873 | 0.69 | GAA (0.57) | MC4R | |
| SCHEMBL7686690 | 0.69 | DRD4 (1.00) | DRD4DRD2POLBMEN1ADRA1D | |
| SCHEMBL8187174 | 0.69 | DRD2 (0.71) | DRD4DRD2ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045626-A1 | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-04-18 | — | — | US | claimed |
| EP-1068193-A1 | BENZYLPIPERAZINYL- AND BENZYLPIPERIDINYL ETHANONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D 4? RECEPTOR ANTAGONISTS | NEUROGEN CORPORATION (US) | 2001-01-17 | — | — | EP | claimed |
| US-6084098-A | HIGH AFFINITY AND SELECTIVITY IN BINDING TO THE D4 RECEPTOR SUBTYPE; NEUROLEPTIC, DOPAMINERGIC AGENTS; SCHIZOPHRENIA, MANIA, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE; ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; PARKINSONISM; TARDIVE DYSKINESIAS; CNS | NEUROGEN CORPORATION (US) | 2000-07-04 | — | — | US | claimed |
| WO-1999043670-A1 | BENZYLPIPERAZINYL- AND BENZYLPIPERIDINYL ETHANONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS | NEUROGEN CORPORATION (US) | 1999-09-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045626-A1 | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands | DRD2, DRD3, OPRD1 | DRD4 4/4885DRD2 1/4885MC4R 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.